Are you at least 21 years old?
You must be at least 21 to see this content, you will be redirected to google
Are you at least 21 years old?
You must be at least 21 to see this content, you will be redirected to google
A
• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)
• attention-deficit-hyperactivity-disorder-adhd (5)
B
C
D
• d9-tetrahydrocannabinol-thc (4)
• d9-tetrahydrocannabinolic-acid-thca (1)
E
• endocannabinoid-system-ecs (45)
F
G
• gastrointestinal-disease (6)
H
I
K
L
M
N
• national-institute-on-drug-abuse-nida (1)
• neuro-protective-and-neuro-generative (7)
P
S
T
• traumatic-brain-injury-tbi (1)
• View All (505)Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy (2010)
These results indicate that the CBD could have an enormous therapeutic potential to treat diabetic and cardiovascular complications due to its ability to reduce inflammation, oxidative stress, nitration, fibrosis and cell death. View study
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study (2005)
According to these experiments of animal models, there is an important relationship between obesity, cardiovascular risks and the CB1 cannabinoid receptor, which when blocked by the inverse agonist Rimonabant promotes the decrease in body weight and waist circumference, also decreasing the cardiovascular risk. View study
Presence of functional cannabinoid receptors in human endocrine pancreas (2007)
The stimulation with CB1 was able to increase the secretion of insulin and glucagon, as well as the lipogenesis in the liver and adipose tissue, blocking the incorporation of glucose in the muscle cells, which led to a saving cycle: lower expenditure energy and greater energy storage. The improved release of insulin can help facilitate the incorporation of glucose into the adipocytes, while the improved release of glucagon can maintain high levels of plasma glucose, which favors this saving cycle. Under this hypothesis, CB1 can be considered a new ’thrifty gene’. In light of this possible role, the endocannabinoid system can be considered a promising target for the pharmacological development in diabetes and complicated obesity. View study
The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications (2012)
It has been previously shown that the modulation of the endocannabinoid system can have an enormous therapeutic potential in a wide range of diseases. This study focuses on the role of the endocannabinoid system in primary diabetes and its effects on various diabetic complications. View study